Biopharma decisions are accelerating, but traditional insight cycles don't always keep pace. In this IQVIA white paper, learn how Synthetic Advisory Boards (S-ABs) use AI-enabled digital twins—under human medical and behavioral-science oversight—to pressure-test evidence, messages, and scenarios before engaging scarce HCP time. Used alongside live advisory boards, S-ABs help teams iterate faster while keeping rigor and transparency front and center.
NACHO QUINONES, PhD, Senior Principal, Global Data Technology and Advisory Services, IQVIA
AISLING O’LOUGHLIN, PhD, Principal, Global Data Technology and Advisory Services, IQVIA
ASEEM SHRIVASTAVA, Data Science Consultant, Innovation and AI Strategy, IQVIA-X
JOVANA BOLIC, PhD, Manager, Medical Affairs Strategy, IQVIA
IRA ARORA, Manager, Medical Affairs Strategy, IQVIA
Leverage real-time insights and AI-driven solutions to connect with HCPs and patients, ensuring effective engagement, improved patient outcomes, and rapid response to market dynamics.
.svg){kind=icon}
